SG Americas Securities LLC Buys 113,909 Shares of Amgen Inc. $AMGN

SG Americas Securities LLC grew its position in shares of Amgen Inc. (NASDAQ:AMGN) by 40.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 397,219 shares of the medical research company’s stock after acquiring an additional 113,909 shares during the quarter. SG Americas Securities LLC’s holdings in Amgen were worth $130,014,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Sequoia Financial Advisors LLC lifted its holdings in Amgen by 2.3% during the third quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock worth $45,334,000 after acquiring an additional 3,619 shares during the period. Davis Capital Management purchased a new position in Amgen in the third quarter worth $1,841,000. D.A. Davidson & CO. grew its stake in Amgen by 2.6% in the 3rd quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock valued at $68,590,000 after purchasing an additional 6,222 shares during the period. Global Wealth Management Investment Advisory Inc. grew its stake in Amgen by 56.2% in the 3rd quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company’s stock valued at $3,684,000 after purchasing an additional 4,699 shares during the period. Finally, Jones Financial Companies Lllp increased its position in shares of Amgen by 18.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 39,778 shares of the medical research company’s stock valued at $10,888,000 after purchasing an additional 6,115 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Daiwa Securities Group lifted their target price on Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 10th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a report on Thursday, February 5th. Rothschild & Co Redburn lifted their price objective on shares of Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research report on Wednesday, February 18th. BMO Capital Markets boosted their target price on shares of Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a research note on Wednesday, December 3rd. Finally, Leerink Partners reissued a “market perform” rating and set a $355.00 target price on shares of Amgen in a research report on Thursday, March 5th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $354.60.

Amgen Stock Up 0.6%

AMGN stock opened at $349.77 on Tuesday. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The company has a market capitalization of $188.55 billion, a price-to-earnings ratio of 24.58, a PEG ratio of 3.45 and a beta of 0.45. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $391.29. The stock has a fifty day moving average of $360.77 and a 200-day moving average of $328.60.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same quarter last year, the firm posted $5.31 EPS. The firm’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. Amgen’s dividend payout ratio (DPR) is presently 70.84%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.